Insulin and diabetes drugs pull glucose out of the blood and out of the cells, producing an internal 'famine'.
Original statement
الأنسولين وأدوية السكر تسحب السكر من الدم والخلايا، فتسبب «مجاعة» داخل الجسم
not verbatim – paraphrase. Translation by the project; the Arabic wording is authoritative.
Translation
Insulin and diabetes drugs pull glucose out of the blood and out of the cells, producing an internal 'famine'.
Origin
- Source status
- Archive quote (no location given)
- Attribution
- Elawady (archive paraphrase; source video not given)
- Origin
- https://eltayebat.com/rule/oral-diabetes-drugs/
- Attribution uncertainty
- The archive attributes this text to Dr. Diaa in its 'د. ضياء يقول' box but gives no video reference. Transcript check (the project's research files, keyword search of 307 archive transcripts): similar_idea_only. The image of an 'internal famine' (مجاعة) was found in his transcripts only in other contexts (fasting, war), not in relation to insulin or diabetes drugs. A passage stating that anyone who lowers blood sugar or takes insulin, Galvus, Forxiga or Mounjaro will be harmed (5Pr4BCDlQeI) expresses a related idea.
- Claimed mechanism
Glucose-lowering drugs deprive cells of fuel.
- Claimed health effect
Cell starvation
- Population concerned
People taking glucose-lowering drugs
- Geographic restriction by Elawady
none found
Diverging source versions
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- Dr Diaa Al Awady د ضياء العوضي is live!فلسفة الصيام مع السحور المحترم (Open source)
- Published
- 23 February 2026
- Timestamp
- not available (transcript has no timings)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; 'published' is the date listed by the archive and may be the upload date. Live-stream transcripts can contain viewer comments read aloud; the quoted passage was checked in context to be spoken by Elawady.
اللي هيوطي السكر هيتفشخ اللي هياخد انسولين هيتفشخ اللي هياخد دوا جالفس هيتفشخ اللي هياخد فورسيجا هيتفشخ اللي هياخد مونجارو هيتفشخ
Whoever lowers the sugar will be wrecked; whoever takes insulin will be wrecked; whoever takes the drug Galvus will be wrecked; whoever takes Forxiga will be wrecked; whoever takes Mounjaro will be wrecked (vulgar colloquial verb).
- Source status
- Video transcript (own words)
- Attribution
- Elawady (machine transcript)
- Video
- بدأت قناة ＂Dr Diaa Al Awady د ضياء العوضي＂ بثًا مباشرًا ذكري يوم ميلادي 😂😂❤️❤️❤️ (Open source)
- Published
- 26 March 2026
- Timestamp
- 1:16:57 (location in the original video’s automatic YouTube caption track; confirms where the words occur, not who speaks)
- Attribution uncertainty
- Archive transcript (YouTube CC or AI-generated); no timestamps; YouTube original not checked; wording may contain recognition errors. Similar idea only; the 'famine' image is not in this passage.
Scientific assessment
Mostly false – Essential parts of the statement are not supported by the evidence or are strongly exaggerated.
Certainty of evidence: high – Further research is very unlikely to change the assessment.
1. What was claimed?
Diabetes drugs starve the body by removing glucose from blood and cells.
2. What is demonstrably correct?
Insulin and sulfonylureas can cause hypoglycaemia, which deprives the brain of glucose; this is the main harm of over-treatment (A-INS-14, A-INS-15, A-INS-16). Severe hypoglycaemia is uncommon and mainly a marker of vulnerability (A-INS-14, A-INS-15). SGLT2 inhibitors can cause a starvation-like ketotic state in some situations (I-ODD-10).
3. What is wrong or exaggerated?
In hyperglycaemia the problem is not lack of glucose in the blood but too much; insulin moves glucose into muscle and fat cells where it is used or stored, so cells are not starved. Insulin deficiency, not insulin, produces an internal 'famine' with breakdown of fat and muscle (I-INS-08).
4. What remains unclear?
No study has tested an 'internal famine' concept because it is not a defined physiological state. The archive's wording ('internal famine') was found in Elawady's transcripts only in other contexts (fasting, war), so it is uncertain whether he used this image for insulin.
5. Which studies support it?
None for an 'internal famine'. Mixed: A-INS-14, A-INS-15 (hypoglycaemia kernel only; hypoglycaemia uncommon and mostly a marker of vulnerability), I-ODD-10.
6. Which studies contradict it?
7. What applies to Germany and Europe?
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
8. What is known about Egypt?
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
9. What practical conclusion is appropriate?
Hypoglycaemia is a real risk that requires dose adjustment and education; it is not a general property of diabetes treatment.
Assessment details
- Rationale for certainty of evidence
Glucose-lowering drugs act by increasing glucose uptake into tissues (insulin), reducing hepatic glucose output (metformin), or excreting excess glucose (SGLT2). Only overdose/hypoglycaemia deprives the brain of glucose. The 'famine' concept has no empirical support apart from that kernel.
- Source quality
Archive paraphrase plus own words.
- Regional transferability
Universal.
- Individual exceptions
Older or frail people and those on insulin/sulfonylureas are at higher hypoglycaemia risk.
- Regional scope of the claim
- general (biological/medical)
- Last reviewed
- 25 October 2026 provisional
In plain language
Diabetes drugs do not starve the body. Insulin, for example, helps sugar get into muscle cells where it is needed. The real risk is a dose that is too high, causing low blood sugar, which doctors try to prevent by adjusting the dose.
Studies on this claim
Studies supporting the claim (0)
No studies in this group.
Studies contradicting or limiting the claim (2)
-
Review on diabetic ketoacidosis
Dhatariya KK et al.. Nat Rev Dis Primers 2020 · PMID 32409703 · DOI 10.1038/s41572-020-0165-1Narrative reviewindependent cross-checkfull text checkedDKA is an emergency that can kill; it is treated with fluids, insulin and salts, and insulin must not be stopped in type 1 diabetes even when not eating.
Does the study support the specific claim? No · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Epidemiology, pathogenesis, diagnosis and management of DKA
- How was the study done?
Narrative expert review (Nature Reviews Disease Primers)
- How many people, animals or samples were studied?
not applicable; Adults and children with diabetes
- What was actually found?
DKA is diagnosed by high glucose, ketones and acid; it kills <1% when treated in rich countries but up to 26-41% where treatment is lacking; treatment is fluids, insulin and potassium, and insulin must never be stopped in type 1 diabetes even when not eating.
- How large was the observed effect?
not applicable
- What do the results mean in everyday life?
DKA is an emergency.
- What are the study's limitations?
Narrative expert review without systematic methods; one author has research support from insulin makers.
- What does it say about Elawady's specific claim?
- Do the results apply to Germany and Europe?
International.
- What can explicitly not be concluded from this study?
Quantitative estimates.
-
DCCT: better insulin treatment in type 1 diabetes
Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401Randomised controlled trialindependent cross-checkabstract only checked★ key studyIntensive insulin cut the risk of eye damage by three-quarters and nerve damage by 60%, with more low-sugar episodes.
Does the study support the specific claim? No · Methodological quality: high · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Does intensive insulin therapy reduce long-term complications in type 1 diabetes?
- How was the study done?
Multicentre RCT (DCCT)
- How many people, animals or samples were studied?
1,441; Insulin-dependent (type 1) diabetes
- What was actually found?
Large reductions in all microvascular complications.
- How large was the observed effect?
Retinopathy -76%
- What do the results mean in everyday life?
Insulin protects eyes, kidneys and nerves in type 1 diabetes.
- What are the study's limitations?
Open-label; Selected young population
- What does it say about Elawady's specific claim?
Contradicts C-INS-07, C-INS-09, C-DIAB-01; shows insulin efficacy and hypoglycaemia cost (C-INS-02 kernel).
- Do the results apply to Germany and Europe?
North American; universally accepted.
- What can explicitly not be concluded from this study?
Effects in type 2 diabetes directly.
No study in this group is marked as key.
Studies with mixed or unclear results (3)
-
Ketoacidosis with normal blood sugar on SGLT2 drugs
Peters AL et al.. Diabetes Care 2015 · PMID 26078479 · DOI 10.2337/dc15-0843Case series / case reportindependent cross-checkfull text checkedSeveral patients developed ketoacidosis with near-normal sugar, so it was recognised late.
Does the study support the specific claim? Yes · Methodological quality: very low · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Describe euglycaemic DKA with SGLT2 inhibitors
- How was the study done?
Case series
- How many people, animals or samples were studied?
9 individuals, 13 episodes; Patients with T1D or T2D on SGLT2 inhibitors
- What was actually found?
13 episodes in 9 patients on canagliflozin (7 with off-label type 1 diabetes); glucose often near normal, delaying diagnosis; all recovered with IV fluids and insulin.
- How large was the observed effect?
not applicable
- What do the results mean in everyday life?
Check ketones when unwell on SGLT2 drugs.
- What are the study's limitations?
Incidental case collection, no denominator, mostly off-label type 1 use, all on canagliflozin.
- What does it say about Elawady's specific claim?
- Do the results apply to Germany and Europe?
US.
- What can explicitly not be concluded from this study?
How often this happens; that every SGLT2 inhibitor (e.g. dapagliflozin) carries the same risk (inferred, not shown here).
-
Severe low blood sugar and death in ACCORD
Bonds DE et al.. BMJ 2010 · PMID 20061358 · DOI 10.1136/bmj.b4909Cohort studycited by the Tayebat archivefull text checked★ key studyPeople who had severe low-sugar episodes died more often, but this did not explain why the intensive group had more deaths.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Link between severe hypoglycaemia and mortality in ACCORD
- How was the study done?
Retrospective epidemiological analysis within an RCT (ACCORD)
- How many people, animals or samples were studied?
10,194; ACCORD participants with hypoglycaemia assessment
- What was actually found?
Deaths were more common after severe low-sugar episodes (adjusted HR 1.41 and 2.30), but only 1 of 451 deaths was definitely caused by low sugar, and it explained only about 5 of 57 extra deaths in the intensive group.
- How large was the observed effect?
aHR 1.41 (1.03-1.93) intensive arm
- What do the results mean in everyday life?
Severe hypoglycaemia is a danger sign to avoid.
- What are the study's limitations?
Post-hoc observational analysis; Confounding by frailty
- What does it say about Elawady's specific claim?
Supports C-INS-04 (hypoglycaemia is a marker of risk); limits causal interpretation.
- Do the results apply to Germany and Europe?
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- What can explicitly not be concluded from this study?
That hypoglycaemia caused the ACCORD excess mortality.
-
Severe hypoglycaemia in ADVANCE
Zoungas S et al.. N Engl J Med 2010 · PMID 20925543 · DOI 10.1056/NEJMoa1003795Cohort studycited by the Tayebat archivefull text checkedSevere low-sugar episodes were followed by more heart events and deaths, probably partly because frail people get them.
Does the study support the specific claim? Partly · Methodological quality: moderate · Certainty of evidence: see overall assessment of the claim
Original publication · Scientific details
Study explained simply
- What did the researchers want to find out?
Severe hypoglycaemia and vascular events/death
- How was the study done?
Post-hoc cohort analysis of an RCT (ADVANCE)
- How many people, animals or samples were studied?
11,140; ADVANCE participants with type 2 diabetes
- What was actually found?
aHR 2.69 death.
- How large was the observed effect?
aHR 2.69 (1.97-3.67)
- What do the results mean in everyday life?
Avoid severe hypoglycaemia.
- What are the study's limitations?
Only 231 people had severe hypoglycaemia; links also seen with skin and digestive disease (suggesting frailty); no dose-response; intensive treatment was a sulfonylurea, not insulin; funded by the drug's manufacturer.
- What does it say about Elawady's specific claim?
- Do the results apply to Germany and Europe?
Multinational/US/UK/European data; directly transferable to Germany/EU clinical practice.
- What can explicitly not be concluded from this study?
Causation.
No study in this group is marked as key.
Regional context
Germany / EU
European (EASD) and German (DDG) guidance follow the same evidence base as the ADA/EASD consensus: individualised HbA1c targets, insulin as mandatory therapy in type 1 diabetes, and SGLT2 inhibitors/GLP-1 receptor agonists for people with cardiovascular or kidney disease. No country-specific difference changes the assessment.
Egypt
Egypt has one of the highest diabetes prevalences in the region; the same drug classes and insulins are used. Access barriers and cost may make advice to stop medication attractive, which increases the practical risk of this claim. No Egypt-specific evidence changes the assessment.
What applies in my country?
General scientific assessment
Mostly false Diabetes drugs do not starve cells; the real risk is hypoglycaemia from overdosing.
This statement concerns biological or medical relationships. The scientific assessment above applies regardless of the country; country-specific food data do not change it.
References
- Diabetic ketoacidosis.. Dhatariya KK et al.. Nat Rev Dis Primers 2020 · PMID 32409703 · DOI 10.1038/s41572-020-0165-1
- The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus.. Diabetes Control and Complications Trial Research Group; Nathan DM et al.. N Engl J Med 1993 · PMID 8366922 · DOI 10.1056/NEJM199309303291401
- Euglycemic Diabetic Ketoacidosis: A Potential Complication of Treatment With Sodium-Glucose Cotransporter 2 Inhibition.. Peters AL et al.. Diabetes Care 2015 · PMID 26078479 · DOI 10.2337/dc15-0843
- The association between symptomatic, severe hypoglycaemia and mortality in type 2 diabetes: retrospective epidemiological analysis of the ACCORD study.. Bonds DE et al.. BMJ 2010 · PMID 20061358 · DOI 10.1136/bmj.b4909
- Severe hypoglycemia and risks of vascular events and death.. Zoungas S et al.. N Engl J Med 2010 · PMID 20925543 · DOI 10.1056/NEJMoa1003795